Latest News and Press Releases

The Swedish Medical Product Agency has approved a first-in-human study, NZ-DTX-001, in which solid tumors will be treated with NanoZolid combined with docetaxel. This is LIDDS' second clinical...

Vid årsstämman i LIDDS AB (publ) den 16 maj 2018 beslutades att en valberedning skall utses och bestå av tre ledamöter, utsedda av de två största aktieägarna per den 30 september 2018, jämte...

At BIO-Europe 2018, LIDDS will be meeting potential licensing and collaborative partners, to discuss the recently announced pre-clinical studies with NanoZolid-technology. The STING study is yet...

The European Patent Office has approved a novel patent for LIDDS NanoZolid® technology. LIDDS patent protection for the drug delivery technology is now extended for at least another nineteen years. ...

ANDRA KVARTALET (APRIL - JUNI 2018) Nettoomsättningen uppgick till 0,0 (0,4) MSEK Kostnaderna uppgick till 2,2 (1,6) MSEK Resultatet före och efter skatt uppgick till -2,2 (-1,2) MSEK ...

The preclinical study proves that a single intratumoral injection of a NanoZolid® formulated STING-agonist has equal or better efficacy compared to multiple injections of a standard STING-agonist...

LIDDS has agreed to transfer the licensing agreement for Liproca® Depot in China to Jiangxi Puheng Pharmaceuticals Ltd following a request from the owners of Jiangsu Ambition Medical. The change of...

   The international Journal of Drug Delivery Science and Technologywill publish the scientific article in the August edition titled "Cold isostatic pressing of hydrating calcium sulfate as a means...

LIDDS AB (publ) has decided on a direct share issue to Nyenburgh Holding BV, AESCAP 2.0 and BWG Invest, all being international funds that invests in closely selected European biotech- and pharma...

The European patent office has approved LIDDS' patent related to devices and methods of injection. The patent is now approved in all major markets and provides protection for all drug formulations...